首页> 外文期刊>Experimental Eye Research >Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1 Delta E9 mice and its immunomodulatory mechanisms
【24h】

Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1 Delta E9 mice and its immunomodulatory mechanisms

机译:美金刚对APPswe / PS1 Delta E9小鼠视网膜神经节细胞的神经保护作用及其免疫调节机制

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Besides the cognitive impairment and degeneration in the brain, vision dysfunction and retina damage are always prevalent in patients with Alzheimer's disease (AD). The uncompetitive antagonist of the N-methyl-D-aspartate receptor, memantine (MEM), has been proven to improve the cognition of patients with AD. However, limited information exists regarding the mechanism of neurodegeneration and the possible neuroprotective mechanisms of MEM on the retinas of patients with AD. In the present study, by using APP5we/PS1 Delta E9 double transgenic (dtg) mice, we found that MEM rescued the loss of retinal ganglion cells (RGCs), as well as improved visual impairments, including improving the P50 component in pattern electroretinograms and the latency delay of the P2 component in flash visual evoked potentials of APPswe/PS1 Delta E9 dtg mice. The activated microglia in the retinas of APPswe/PS1 Delta E9 dtg mice were also inhibited by MEM. Additionally, the level of glutamine synthetase expressed by Muller cells within the RGC layer was upregulated in APPswe/PS1 Delta E9 dtg mice, which was inhibited by MEM. Simultaneously, MEM also reduced the apoptosis of choline acetyl transferase-immunoreactive cholinergic amacrine cells within the RGC layer of AD mice. Moreover, the phosphorylation level of extracellular regulated protein kinases 1 and 2 was increased in APPswe/PS1 Delta E9 dtg mice, which was blocked by MEM treatment. These findings suggest that MEM protects RGCs in the retinas of APPswe/PS1 Delta E9 dtg mice by modulating the immune response of microglia and the adapted response of Muller cells, making MEM a potential ophthalmic treatment alternative in patients with AD. (C) 2015 Elsevier Ltd. All rights reserved.
机译:除了大脑的认知障碍和退化之外,阿尔茨海默氏病(AD)患者的视力障碍和视网膜损害也始终很普遍。 N-甲基-D-天冬氨酸受体的非竞争性拮抗剂美金刚胺(MEM)已被证明可以改善AD患者的认知能力。但是,关于神经变性的机制以及MEM对AD患者视网膜的可能神经保护机制的信息有限。在本研究中,通过使用APP5we / PS1 Delta E9双转基因(dtg)小鼠,我们发现MEM挽救了视网膜神经节细胞(RGCs)的丢失,并改善了视力障碍,包括改善了模式视网膜电图中的P50成分和APPswe / PS1 Delta E9 dtg小鼠的闪光视觉诱发电位中P2组分的潜伏延迟。 MEM也抑制了APPswe / PS1 Delta E9 dtg小鼠视网膜中的活化小胶质细胞。此外,在APPswe / PS1 Delta E9 dtg小鼠中,RGC层中Muller细胞表达的谷氨酰胺合成酶水平被上调,但被MEM抑制。同时,MEM还减少了AD小鼠RGC层内胆碱乙酰基转移酶免疫反应性胆碱能无长蛋白细胞的凋亡。此外,在APPswe / PS1 Delta E9 dtg小鼠中,细胞外调节蛋白激酶1和2的磷酸化水平增加,这被MEM处理所阻断。这些发现表明,MEM通过调节小胶质细胞的免疫反应和穆勒细胞的适应性反应来保护APPswe / PS1 Delta E9 dtg小鼠视网膜中的RGC,从而使MEM成为AD患者潜在的眼科治疗选择。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号